Three Drugs Given Together for Glioma That Came Back or Did Not Respond

Official title: Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This study is testing whether three drugs given together can help people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary came back or did not get better with earlier treatment.

Read our full plain-language summary

What the trial team says

This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT05188508
Stage of testing
Phase 2
Conditions studied
Glioma

Where it is running

This trial lists 10 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.